CDXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Codexis's EBITDA for the three months ended in Sep. 2024 was $-13.68 Mil. Codexis's Revenue for the three months ended in Sep. 2024 was $12.83 Mil. Therefore, Codexis's EBITDA margin for the quarter that ended in Sep. 2024 was -106.63%.
The historical data trend for Codexis's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBITDA Margin % | Get a 7-Day Free Trial | -11.67 | -28.04 | -15.99 | -15.49 | -63.98 |
Codexis Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EBITDA Margin % | Get a 7-Day Free Trial | -307.41 | 46.15 | -57.77 | -247.00 | -106.63 |
For the Biotechnology subindustry, Codexis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Codexis's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Codexis's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Codexis's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
Codexis's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis (NAS:CDXS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of Codexis's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Byron L Dorgan | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Kevin Norrett | officer: Chief Operating Officer | C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
Margaret Nell Fitzgerald | officer: See Remarks | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Sriram Ryali | officer: Chief Financial Officer | C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306 |
Stephen George Dilly | director, officer: See Remarks | C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
John J Nicols | director, officer: President and CEO | ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801 |
H Stewart Parker | director | |
Rahul Singhvi | director | 246 HOLLY DRIVE, CHALFONT PA 18914 |
Dennis P Wolf | director | 1101 EAST MEADOW DR, PALO ALTO CA 94303 |
Patrick Y Yang | director | C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990 |
Bernard J Kelley | director | |
Esther Martinborough | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Jennifer Aaker | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Alison Moore | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Thomas R Baruch | director | 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129 |
From GuruFocus
By GuruFocus News • 11-01-2024
By Marketwired • 07-01-2024
By Marketwired • 09-03-2024
By Marketwired • 08-15-2024
By Marketwired • 10-10-2024
By Marketwired • 09-06-2024
By Marketwired • 08-16-2024
By Marketwired • 08-08-2024
By Marketwired • 05-22-2024
By GuruFocus News • 10-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.